Chronic Kidney Disease Market Growth Projections 2024-2034: DelveInsight Analysis | Tricida, Otsuka Pharma, AstraZeneca

The Key Chronic Kidney Disease Companies in the market include - Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others.

The Chronic Kidney Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Kidney Disease pipeline products will significantly revolutionize the Chronic Kidney Disease market dynamics.

DelveInsight's "Chronic Kidney Disease Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Chronic Kidney Disease, historical and forecasted epidemiology as well as the Chronic Kidney Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Chronic Kidney Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Chronic Kidney Disease Market Forecast [https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Chronic Kidney Disease Market Report:

*
The Chronic Kidney Disease market size is anticipated to grow with a significant CAGR during the study period (2020-2034)

*
In November 2024, Unicycive Therapeutics (Nasdaq: UNCY) announced that the U.S. FDA has accepted its New Drug Application (NDA) for Oxylanthanum Carbonate (OLC), with a target action date of June 28, 2025, under the PDUFA. If approved, OLC has the potential to significantly enhance the treatment of hyperphosphatemia in Chronic Kidney Disease patients undergoing dialysis.

*
In October 2024, Maze Therapeutics, a clinical-stage biopharmaceutical company leveraging human genetics to develop innovative small molecule precision medicines for common diseases, has initiated dosing in its Phase 1 clinical trial of MZE782 in healthy volunteers. MZE782 is an oral, first-in-class small molecule designed to target the solute transporter SLC6A19. The drug has the potential to benefit around five million of the 37 million chronic kidney disease (CKD) patients in the U.S. who do not respond adequately to existing CKD treatments.

*
In July 2024, Renalys Pharma has raised 6 billion ($3.8 million) in a Series A funding round to advance clinical trials for kidney disease treatments across Asia. The financing was led by Catalys Pacific and SR One, with additional support from a group of investors, including JPS Growth Investment Limited Partnership, Sumitomo Mitsui Trust Bank, Japan Co-Invest IV Limited Partnership, and NVCC No.9 Investment Limited Partnership.

*
The Chronic Kidney Disease therapeutics market size in the US was approximately USD 2,824 million in 2023 and is expected to grow further during the forecast period.

*
In 2023, the United Kingdom had the largest Chronic Kidney Disease market size among the EU countries, with nearly USD 421 million, while Italy recorded the smallest market size at approximately USD 132 million.

*
The Chronic Kidney Disease therapeutics market size in Japan was estimated at around USD 1,402 million in 2023.

*
According to DelveInsight's analysis, the total diagnosed prevalent cases of Chronic Kidney Disease in the 7MM were approximately 16 million in 2023.

*
In 2023, the United States held the largest Chronic Kidney Disease market size among the 7MM, valued at around USD 2,824 million, with projections indicating further growth by 2034.

*
In 2023, the United States reported the highest prevalence of Chronic Kidney Disease among the 7MM, with approximately 40 million cases, and this number is projected to grow by 2034.

*
The Chronic Kidney Disease market in 2023, valued at USD 5,479 million across the 7MM, primarily consists of erythropoietin-stimulating agents (ESAs), ACE inhibitors, angiotensin receptor blockers (ARBs), antidiabetic medications, treatments for secondary hyperparathyroidism (SHPT), and urate-lowering therapies. The market is anticipated to expand further with the introduction of emerging therapies during the forecast period (2024-2034).

*
In 2023, Japan's Chronic Kidney Disease market size was valued at USD 1,402 million, with projections indicating substantial growth at a notable CAGR by 2034.

*
In 2023, the United Kingdom had the highest number of diagnosed prevalent cases of Chronic Kidney Disease among European countries, with around 2 million cases, followed by Germany with approximately 1 million cases. Italy, on the other hand, had the lowest prevalent population, totaling 731 thousand cases.

*
In 2023, Japan reported nearly 3 million total diagnosed prevalent cases of Chronic Kidney Disease, representing about 22% of the total cases across the 7MM.

*
DelveInsight's analysis shows that in the EU4 and the UK, more females are impacted than males, with approximately 3.55 million female cases and 3.4 million male cases in 2023.

*
Key Chronic Kidney Disease Companies: Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others

*
Key Chronic Kidney Disease Therapies: TRC101 (Veverimer), Tolvaptan, AZD5718, and others

*
The Chronic Kidney Disease epidemiology based on gender analyzed that Chronic Kidney Disease is slightly more common in women (14%) than men (12%)

Chronic Kidney Disease Overview

Chronic Kidney Disease (CKD) is a long-term condition characterized by a gradual loss of kidney function over time. The kidneys play a crucial role in filtering waste, toxins, and excess fluids from the blood. In CKD, this filtering ability is impaired, leading to a buildup of harmful substances in the body.

The condition is often caused by underlying health issues such as diabetes, high blood pressure, or glomerulonephritis. Symptoms may not appear until the disease is advanced and can include fatigue, swelling, nausea, and difficulty concentrating. Left untreated, CKD can progress to kidney failure, requiring dialysis or a kidney transplant. Early detection and management, including lifestyle changes and medications, can help slow disease progression.

Get a Free sample for the Chronic Kidney Disease Market Report:

https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market [https://www.delveinsight.com/report-store/chronic-kidney-disease-chronic-renal-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Chronic Kidney Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Chronic Kidney Disease Epidemiology Segmentation:

The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Chronic Kidney Disease

*
Prevalent Cases of Chronic Kidney Disease by severity

*
Gender-specific Prevalence of Chronic Kidney Disease

*
Diagnosed Cases of Episodic and Chronic Chronic Kidney Disease

Download the report to understand which factors are driving Chronic Kidney Disease epidemiology trends @ Chronic Kidney Disease Epidemiology Forecast [https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Chronic Kidney Disease Epidemiology Segmentation:

The Chronic Kidney Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Chronic Kidney Disease

*
Prevalent Cases of Chronic Kidney Disease by severity

*
Gender-specific Prevalence of Chronic Kidney Disease

*
Diagnosed Cases of Episodic and Chronic Chronic Kidney Disease

Chronic Kidney Disease Market

The dynamics of the Chronic Kidney Disease market are anticipated to change in the coming years owing to the expected launch of emerging therapies and others during the forecasted period 2020-2034.

"Although the pipeline for the treatment of Chronic Kidney Disease looks robust, most of the investigational therapies aim at improving kidney function (measured by improved renal output), there are no curative therapies in development that aim to regain kidney function."

Chronic Kidney Disease Therapies and Key Companies

*
TRC101 (Veverimer): Tricida

*
Tolvaptan: Otsuka Pharmaceuticals

*
AZD5718: AstraZeneca

To know more about Chronic Kidney Disease treatment, visit @ Chronic Kidney Disease Medications [https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Chronic Kidney Disease Market Drivers

*
Rising Prevalence of CKD

*
Advancements in Diagnostic Tools

*
Development of Novel Therapies

*
Increased Healthcare Spending

*
Awareness Campaigns

*
Favorable Regulatory Approvals

Chronic Kidney Disease Market Barriers

*
High Treatment Costs

*
Limited Access to Healthcare

*
Late Diagnosis

*
Side Effects of Therapies

*
Regulatory Hurdles

*
Patient Adherence Issues

Scope of the Chronic Kidney Disease Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Chronic Kidney Disease Companies: Tricida, Otsuka Pharmaceuticals, AstraZeneca, and others

*
Key Chronic Kidney Disease Therapies: TRC101 (Veverimer), Tolvaptan, AZD5718, and others

*
Chronic Kidney Disease Therapeutic Assessment: Chronic Kidney Disease current marketed and Chronic Kidney Disease emerging therapies

*
Chronic Kidney Disease Market Dynamics: Chronic Kidney Disease market drivers and Chronic Kidney Disease market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Chronic Kidney Disease Unmet Needs, KOL's views, Analyst's views, Chronic Kidney Disease Market Access and Reimbursement

Discover more about therapies set to grab major Chronic Kidney Disease market share @ Chronic Kidney Disease Treatment Landscape [https://www.delveinsight.com/sample-request/chronic-kidney-disease-chronic-renal-failure-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Chronic Kidney Disease Market Report Introduction

2. Executive Summary for Chronic Kidney Disease

3. SWOT analysis of Chronic Kidney Disease

4. Chronic Kidney Disease Patient Share (%) Overview at a Glance

5. Chronic Kidney Disease Market Overview at a Glance

6. Chronic Kidney Disease Disease Background and Overview

7. Chronic Kidney Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Chronic Kidney Disease

9. Chronic Kidney Disease Current Treatment and Medical Practices

10. Chronic Kidney Disease Unmet Needs

11. Chronic Kidney Disease Emerging Therapies

12. Chronic Kidney Disease Market Outlook

13. Country-Wise Chronic Kidney Disease Market Analysis (2020-2034)

14. Chronic Kidney Disease Market Access and Reimbursement of Therapies

15. Chronic Kidney Disease Market Drivers

16. Chronic Kidney Disease Market Barriers

17. Chronic Kidney Disease Appendix

18. Chronic Kidney Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-kidney-disease-market-growth-projections-20242034-delveinsight-analysis-tricida-otsuka-pharma-astrazeneca]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.